COMMUNIQUÉS West-GlobeNewswire

Telix Pharmaceuticals Limited lance une introduction en bourse de 50 millions de dollars (ASX : TLX)

24/10/2017 - 21:12

MELBOURNE, Australie, le 24 octobre 2017 (GLOBE NEWSWIRE) - Telix Pharmaceuticals Limited ( Telix , la Société ), une société biopharmaceutique australienne axée sur le développement de produits de diagnostic et [...]

Telix Pharmaceuticals et ANMI s'associent en partenariat pour l'imagerie du cancer de la prostate

24/10/2017 - 18:11

MELBOURNE, Australie et LIÈGE, Belgique, 2017-10-24 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ( Telix, la Société ), une société biopharmaceutique au stade clinique axée sur le développement de produits de [...]

DDF notes major collaboration between portfolio company Alector and AbbVie to advance novel class of immune therapies for patients with Alzheimer's disease

24/10/2017 - 15:27

DDF notes major collaboration between portfolio company Alector and AbbVie to advance novel class of immune therapies for patients with Alzheimer's disease DDF invested in San Francisco company Alector in Q4 2015 [...]

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

24/10/2017 - 12:43

Company announcement - No. 48/2017 U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) [...]

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference

24/10/2017 - 11:40

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference Lausanne, Switzerland, - October 24, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical [...]

Orphazyme announces intention to launch an Initial Public Offering

24/10/2017 - 08:19

Company announcement Orphazyme A/S No. 1/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 24 October 2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART [...]

Nicox : Point d'activité du troisième trimestre 2017 et position de trésorerie

24/10/2017 - 07:30

Communiqué de presse Nicox : Point d'activité du troisième trimestre 2017 et position de trésorerie Accord de licence avec Eyevance Pharmaceuticals pour une commercialisation de ZERVIATE TM1 aux Etats-Unis prévue fin [...]

Nicox Provides Third Quarter 2017 Business Update and Cash Position

24/10/2017 - 07:30

Press Release Nicox Provides Third Quarter 2017 Business Update and Cash Position ZERVIATE TM1 U.S. Rights Licensed to Eyevance Pharmaceuticals - Launch Expected Late 2018 Two New Collaborations in Place for Development [...]

Idorsia announces financial results as of 30 September 2017

24/10/2017 - 07:00

Allschwil, Switzerland - 24 October 2017 - Idorsia Ltd (SIX: IDIA) today announced its financial results as of 30 September 2017, which represent the business activity in the three and a half months since the demerger [...]

Novartis delivered growth on top and bottom line in all divisions in Q3

24/10/2017 - 07:00

Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew driven by improved access and [...]

Novartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisions

24/10/2017 - 07:00

Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses indications Entresto (USD 128 [...]

Targovax ASA: Invitation to third quarter 2017 results presentation Thursday 2 November

24/10/2017 - 07:00

Oslo, Norway, 24 October 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its third quarter 2017 results on Thursday, 2 [...]

Bone Therapeutics SA : To participate in upcoming key investor and partnering conferences in Q4 2017

24/10/2017 - 07:00

Press release Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017 Gosselies, Belgium, 24 October 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the [...]

Bone Therapeutics SA annonce sa participation à plusieurs conférences investisseurs et business au T4 2017

24/10/2017 - 07:00

Communiqué de presse Bone Therapeutics annonce sa participation à plusieurs conférences investisseurs et business au T4 2017 Gosselies, Belgique, le 24 octobre 2017, 7h CEST - BONE THERAPEUTICS (code Euronext Bruxelles [...]

Essilor - Communiqué : La dynamique s'amplifie / Chiffre d'affaires 9 mois : + 6,6 % hors change

24/10/2017 - 06:30

La dynamique s'amplifie Chiffre d'affaires 9 mois : + 6,6 % hors change Version PDF du communiqué Accélération de la division « Verres et matériel optique » hors effets des catastrophes naturelles Bonnes performances [...]

Essilor - News Release: Gathering Momentum / Nine-month consolidated revenue up 6.6% in constant currency

24/10/2017 - 06:30

Gathering Momentum Nine-month consolidated revenue up 6.6% in constant currency PDF Version of the news release Growth picking up for Lenses & Optical Instruments excluding the impact of natural disasters New [...]

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging

24/10/2017 - 01:00

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ( Telix, Company ), a clinical-stage biopharmaceutical company focused on the development of diagnostic and [...]

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)

23/10/2017 - 23:00

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ( Telix , the Company ), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products [...]

uniQure Announces Proposed Public Offering

23/10/2017 - 22:08

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical [...]